Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended					12 Months Ended
	Jan. 31, 2018	Sep. 30, 2017	Nov. 30, 2016 USD ($)	Sep. 30, 2013 USD ($)	Apr. 30, 2013	Dec. 31, 2017 USD ($) Segment Customer shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Jan. 01, 2018 USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment						2
Number of reporting segments | Segment						2
Foreign currency re-measurement losses						$ 600,000	$ 200,000	$ 70,000
Financial assets level 1 to level 2 transfers amount						0
Financial assets level 2 to level 1 transfers amount						0
Reserves for excess and obsolete inventory						500,000	45,000
Charges for excess and obsolete inventory						400,000	0
Net of allowance for doubtful accounts						4,734,000	6,573,000
Unbilled accounts receivable						$ 3,000,000	1,300,000
Number of major customers | Customer						1
Number of reporting unit | Customer						2
Goodwill impaired						$ 0
Valuation allowance						39,072,000	58,983,000
Reclassification from accumulated other comprehensive loss to net (loss) income						$ 0
One time payment, royalty revenues							14,297,000	$ 3,745,000
Dividend yield						0.00%
Tax benefit from stock-based compensation expense recognized						$ 0	$ 0
Unamortized share-based compensation cost related to non-vested stock options and restricted stock not yet recognized						$ 300,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options and restricted stock						2 years 1 month 6 days
Antidilutive securities excluded from computation of earnings per share | shares						1,981,934	1,658,234	1,087,308
Employee Stock Option [Member]
Schedule Of Significant Accounting Policies [Line Items]
Unamortized share-based compensation cost related to non-vested stock options and restricted stock not yet recognized						$ 2,500,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options and restricted stock						2 years 8 months 12 days
Research and Development [Member]
Schedule Of Significant Accounting Policies [Line Items]
Percentage of reduction in workforce		8.00%
Juniper Pharma Services [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity				$ 3,900,000
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Schedule Of Significant Accounting Policies [Line Items]
Assumed obligation under grant arrangement by the entity				$ 2,500,000		$ 2,500,000
Allergan [Member]
Schedule Of Significant Accounting Policies [Line Items]
One time payment, royalty revenues			$ 11,000,000
Subsequent Event [Member] | Accounting Standards Update No. 2014-09 [Member]
Schedule Of Significant Accounting Policies [Line Items]
Cumulative adjustment to increase retained earnings									$ 5,700,000
Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Additional license and supply agreement renewals term					5 years
License and supply agreement expiration date					May 19, 2020
Merck KGaA [Member] | Subsequent Event [Member]
Schedule Of Significant Accounting Policies [Line Items]
License and supply agreement expiration date	Dec. 31, 2024
Extension term of the supply agreement	4 years 6 months
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life						3 years
Minimum [Member] | Merck KGaA [Member]
Schedule Of Significant Accounting Policies [Line Items]
Revenue recognition, recorded revenue cost plus percentage						20.00%
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life						7 years